A prospective observational study by Syversen et al. found that patients with immune-mediated inflammatory diseases (IMID) had an attenuated serologic response to the standard two-dose vaccine regimen but a third dose was safe and effective.
2023 Proposed Rule for the Quality Payment Program Released
The ACR RISE Registry staff highlights need-to-know information and key changes for the 2023 performance year as outlined in the proposed rule released July 7.
Clinical Challenges in SLE: Glucocorticoids—How Much Is Too Much?
Glucocorticoids remain a prominent part of care for many patients with SLE but can have toxic side effects; this EULAR 2022 session discussed one institution’s approach to lower the dosage.
Refractory Gout Is a Myth: Tips from an Expert
At this EULAR 2022 session, one expert explains why he believes refractory gout is caused by mismanagement and discussed ways around treatment obstacles.
JAK Inhibitors: Are All Promises Fulfilled?
A decade after JAK inhibitors were approved, this EULAR 2022 session looks at whether the drugs have lived up to expectations.
How to Connect with Your Members of Congress During the August Recess
Many members of Congress return to their home states and districts in August, making it a great time to engage them in local conversations about healthcare policies and how they affect rheumatology practices and patients.
Imaging Modalities in Gout: How to Use them in Clinical Practice
This EULAR 2022 session discussed the increasing role of imaging in the diagnosis of gout.
Treating to Target in Gout: The Trouble with Serum Urate
New analyses of treat to target in gout may lead to revisions in some guidelines.
Difficult-to-Treat Lupus: When & How to Use New Therapies
Clinicians have numerous treatment options for SLE; in a EULAR 2022 session, some of the newer therapies were reviewed.
Biologic or Conventional Therapy for Early RA?
A study has shown that in untreated patients with early RA, treatment with methotrexate combined with the biologic therapies abatacept or certolizumab-pegol resulted in greater CDAI remission rates than active conventional therapy with prednisolone, sulfasalazine or hydroxychloroquine.
- « Previous Page
- 1
- …
- 84
- 85
- 86
- 87
- 88
- …
- 805
- Next Page »